Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-04-29 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物独立董事候选人声明-CHI KIT NG（吴智杰）
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate of a company, detailing qualifications, independence criteria, and compliance with regulatory requirements. It does not contain financial data, audit results, or report content. It is not an announcement of voting results or a proxy solicitation but rather a statement related to board/management information, specifically about a director candidate's qualifications and independence. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on director candidacy, not a full report or announcement of a report.
2022-04-29 Chinese
前沿生物关于董事会、监事会换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election and re-election of the company's board of directors and supervisory board members. It details the nomination, qualifications, and backgrounds of the candidates for the new board and supervisory board. The document references compliance with company law and stock exchange listing rules, and it is dated April 30, 2022. There is no financial data, earnings information, or report publication mentioned. The content focuses exclusively on board and management changes, which fits the category of Board/Management Information (MANG). The document length is over 6,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement.
2022-04-29 Chinese
前沿生物前次募集资金使用情况报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "前次募集资金使用情况报告" which translates to "Report on the Use of Previous Fundraising Proceeds." It references regulatory requirements from the China Securities Regulatory Commission (CSRC) and details the use of funds raised from a prior public offering, including amounts raised, usage, balances, and investment projects. The document includes detailed financial figures related to fundraising proceeds, their allocation, and management, as well as compliance with regulatory guidelines on fundraising use. It is not an annual or quarterly report, nor an earnings release or management discussion. It is a detailed report on the use of capital raised, which fits the category of Capital/Financing Update (CAP). The document is substantive and not merely an announcement or certification, so it is not RPA or RNS. Therefore, the best classification is CAP with high confidence.
2022-04-29 Chinese
前沿生物关于召开2021年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2021 Annual General Meeting (AGM) of Frontier Biotech (Nanjing) Co., Ltd., including the date, voting methods, agenda items, and instructions for shareholders. It contains no financial statements or financial performance data but focuses on the meeting logistics, agenda proposals, and voting procedures. The document is lengthy (8597 characters) and is clearly the official notice and materials for the AGM, not the report itself or the voting results. Therefore, it fits the category of AGM Information (AGM-R).
2022-04-29 Chinese
瑞银证券有限责任公司关于前沿生物药业（南京）股份有限公司2021年度募集资金存放与使用情况的核查意见
Regulatory Filings
2022-04-29 Chinese
前沿生物股东大会议事规则（2022年4月）
Governance Information Classification · 100% confidence The document is titled as the "Rules of Procedure for the Shareholders' General Meeting" of a company, detailing the governance structure, procedures for convening and conducting shareholders' meetings, voting rules, and related governance practices. It extensively covers the internal rules and regulations governing the shareholders' meetings, including legal references and procedural details. There is no financial data, earnings information, or report publication announcement. The content is focused on governance and procedural rules rather than financial results or announcements. Therefore, the document fits best under the category of Governance Information (CGR).
2022-04-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.